Stem Cell Innovations signs material transfer agreement to supply Pluricells™ to Stanford University researchers

September 14, 2006 - Stem Cell Innovations (OTCBB: SCLL), a cell biology company that has developed technology capable of creating a broad range of human cells from its patented, pluripotent stem cells, announced today that it has signed an agreement to supply PluriCells™ to researchers at Stanford University. Under the agreement, investigators at Stanford may receive the cells for use in their laboratories.

Stem Cell Innovations PluriCells™ provide an alternative to ES cells and are available for broad based government funding. The company has previously presented data demonstrating its ability to grow PluriCells™ efficiently and reproducibly without feeder layers, and believes they can serve as an attractive alternative to embryonic stem cells (ES) in federally funded labs. “We are very pleased to have concluded this agreement with Stanford, home to several of the leading stem cell scientists, and expect to use it as a model for future academic agreements,” said James H. Kelly, PhD, CEO of Stem Cell Innovations. “Our objective is make our PluriCells™ widely available to researchers, on an institution friendly basis, who can move stem cell biology forward in the US, in their own labs and without the restrictions imposed by Federal regulation.”

PluriCells™ are a type of pluripotent stem cell isolated from fetal tissue that have the ability to become all cell types of the body. Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH funded laboratory. Stem cells derived from fetal germ cells were explicitly excluded from the Presidential ban by the Department of Health and Human Services guidance document of March 19, 2002, that laid out what type of stem cells could and could not be used in Federally funded research (for the actual document see: www.hhs.gov/ohrp/humansubjects/guidance/stemcell.pdf)

PluriCells™ is a Trademark of Stem Cell Innovations, Inc.

● About Stem Cell Innovations, Inc.

SCI is a cell biology company with offices in Scotch Plains, N.J., Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells™, have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations (SCI) is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company’s currently marketed C3A human liver cell-based toxicology offerings.

Contact Information

James H. Kelly

Chief Executive Officer

Stem Cell Innovations, Inc.

Contact via E-mail